IDH1 inhibitor / SignalRx - LARVOL DELTA

Immunotherapy in BTC: The Future Is Now (DocWire) - "Dr. Azad began advocating for personalized immunotherapy, explaining that BTC is uniquely set up for this approach because of the many targetable mutations. Data suggest that targeted modulation of an abnormality may lead us to an immune effect. She started with showcasing IDH1 in the phase 3 ClarIDHy trial, which led to the approval of ivosidenib. However, mouse models have shown that an intact immune system is needed to get the benefit of IDH1 inhibition. IDH1 inhibition combined with anti-CTLA4 inhibition provides a significant antitumor effect, Dr. Azad explained, and this approach should be the basis for further research."

Media quote